Sandoz Takes Aim At Ranbaxy's Generic Nexium Sales Rights

Law360, New York (June 27, 2012, 7:54 PM EDT) -- Sandoz Inc. has asked the U.S. Food and Drug Administration to find that Ranbaxy Laboratories Ltd. forfeited its six-month exclusivity over the sale of a generic version of heartburn drug Nexium, saying it gained approval too late.

India-based Ranbaxy was the first company to submit an abbreviated new drug application for a generic version of AstraZeneca PLC's Nexium, making it eligible for 180 days of exclusive sale rights.

But in a citizen petition dated June 19, Sandoz — Novartis AG's generic pharmaceutical unit — contends that...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.